A large hedge fund investor in Celera Corp. surrendered its 19.3 million shares to Quest Diagnostics Inc. , which bought the Alameda genetic test developer in May.
Biotechnology Value Fund LP withdrew its demand for an appraisal of its shares and accepted the same $8-per-share payout Quest (NYSE: DGX) made to other Celera shareholders. BVF general partner Mark Lampert had said in March that the Quest deal didn't adequately value Celera.
No comments:
Post a Comment